Day: December 4, 2023

Artist’s “Graffiti Collection” debuts at the new XO Palm Beach lounge, in a first-ever private airport lounge takeover

Palm Beach, Florida December 4, 2023: XO, the world’s premier private aviation network, has announced an exclusive partnership with Romero Britto, considered to be the most licensed artist in the world, to celebrate innovation and creativity.

In a first-ever private airport lounge takeover, Britto exclusively debuted his new “Graffiti Collection” at the new XO lounge at Palm Beach International Airport. The collection, inspired by the walls of Britto’s very first studio in Miami — where he had the opportunity to add his own spray-painted, graffiti, color splashes, and freehand messages of hope, happiness, and love — showcases his signature vibrant and optimistic pop art style.

Palm Beach was chosen as the ideal location for the debut of Britto’s new collection as it reigns as one of the most popular destinations for XO Members; with New York and Palm Beach as one of the top city pairs booked through XO, nearly doubling year over year.

Leona Qi, President U.S. at Vista: “We are incredibly excited to collaborate with Romero Britto, a valued XO Member and a global icon in the art world who embodies the spirit of XO. This partnership is a testament to our unwavering commitment to providing our Members with experiences that go beyond flying.”

Romero Britto, Artist and Founder of The Happy Art Movement: “XO has been my passport to seamless travel while connecting with a community of visionaries. I pour my heart and soul into my art, a passion that fuels my existence. I am thrilled to share my artistic journey with a global audience of art aficionados.”

“Graffiti Collection”

The XO community is a dynamic and diverse group of individuals united by a passion for exceptional private travel. With every flight, XO connects visionaries, shaping the future and empowering them to make a lasting impact on the world.

Britto’s new “Graffiti Collection” will be on display throughout the month of December at the XO Lounge at Palm Beach International Airport. XO Members will also have the first opportunity to purchase his new work.

Information
XO | press@flyxo.com

ABOUT XO

XO is revolutionizing the private aviation industry by combining data intelligence with distinct, elevated service to allow you to reach anywhere in the world, anytime, just by reaching for a mobile device.

XO has built an open future for private aviation with more transparency, efficiency, and accessibility than ever before. Members and clients have access to the Vista Members’ fleet of 360+ aircraft and the safety-vetted XO alliance fleet of 2,100+ private aircraft, covering the full spectrum of cabin classes. Flyers can book an entire aircraft or individual seats through the XO mobile app, website, or an XO aviation advisor.

XO is part of Vista — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset free solutions to cover all key aspects of business aviation.

More XO information and news at www.flyxo.com

XO Global LLC is not a direct air carrier and does not operate any aircraft. All flights will be operated by properly licensed U.S. or foreign air carriers. All services are subject to the terms and conditions available at flyxo.com/legal. Fla. Seller of Travel Ref. No. ST42114.

ABOUT Britto
Romero Britto is a self-taught artist from Brazil who uses vibrant, bold and colorful patterns to reflect his optimistic view of the world. His work is influenced by Matisse and Picasso and has been exhibited in over 100 countries. He has also created public art installations for various events and collaborated with many international brands. His style is described as “exuding warmth, optimism and love.”

For more information about the artist visit www.shopbritto.com

Attachments

• XO x BRITTO
• “Graffiti Collection”

GlobeNewswire Distribution ID 1000902396

Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) —  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies, today announced the appointment of Jennifer Fox as its Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph. D as Head of Research and Development and Chief Medical Officer.

“We are thrilled to welcome Tanya and Jen to our executive team,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Tanya is a deeply experienced physician-scientist leader and Jen is a seasoned healthcare finance and corporate development leader. With their decades of industry leadership experience, they will each be an invaluable addition to Zenas as we head into our next phase of growth, advancing multiple global programs in late-stage clinical development with a goal to deliver differentiated I&I directed therapies to patients in need around the world.”

Ms. Fox is an experienced finance and corporate development executive with an extensive track record in corporate finance and healthcare investment banking, advising numerous private and public companies with respect to strategy, financings and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, a publicly traded biotechnology company. She previously served as a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.

Dr. Fischer is a physician-scientist with deep experience in academia and at both pharmaceutical and biotechnology companies, leading early and late-stage research and development programs across multiple therapeutic areas, including neurology and rare diseases. Prior to joining Zenas, she served as Chief Development Officer and Head of Translational Medicine at Biohaven, a publicly traded biopharmaceutical company. Dr. Fischer began her industry career at Bristol Myers Squibb and held R&D leadership roles of increasing responsibility at EMD-Serono, Sanofi-Genzyme and Alnylam. She is a neurologist and held appointments at Yale University School of Medicine following the completion of her Neurology residency at Yale New Haven Hospital. She obtained MD and PhD degrees from the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School and Rutgers University, respectively, and was awarded the prestigious Presidential Early Career Award for Scientists and Engineers (PECASE).

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc. Obexelimab is currently being studied in a global Phase 3 clinical study in patients with IgG4 Related Disease and a global Phase2/3 study in patients with warm autoimmune hemolytic anemia (wAIHA). Clinical development of obexelimab for Multiple Sclerosis and Systemic Lupus Erythematosus is under evaluation.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 3 (SApHiAre) study for the treatment of wAIHA is available at clinicaltrials.gov: NCT05786573.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8987984

การขยายตำแหน่งผู้นำเชิงกลยุทธ์และการปฏิบัติงานช่วยเพิ่มประสิทธิภาพของ Zenas ในการเติบโตในขณะที่ Obexelimab มีความก้าวหน้าในการทดลองทางคลินิกระยะสุดท้ายสำหรับข้อบ่งชี้ด้านการอักเสบและภูมิคุ้มกันวิทยา (I&I) ที่เป็นไปได้หลายประการ

วอลแทม แมสซาชูเซต, Dec. 04, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma บริษัทชีวเภสัชภัณฑ์ระดับโลกที่มุ่งมั่นที่จะเป็นผู้นำในการพัฒนาและทำธุรกิจด้านการรักษาการอักเสบและภูมิคุ้มกันวิทยา (I&I) ทางตรง ในวันนี้ได้ประกาศแต่งตั้ง Jennifer Fox ดำรงตำแหน่งประธานเจ้าหน้าที่ฝ่ายธุรกิจและประธานเจ้าหน้าที่ฝ่ายการเงิน และ MD., PhD., Tanya Fischer ดำรงตำแหน่งหัวหน้าฝ่ายวิจัยและพัฒนาและประธานเจ้าหน้าที่การแพทย์

“เรารู้สึกตื่นเต้นที่ได้ต้อนรับ Tanya และ Jen เข้าสู่ทีมผู้บริหารของเรา” Lonnie Moulder ผู้ก่อตั้งและประธานเจ้าหน้าที่บริหารของ Zenas BioPharma กล่าว “Tanya เป็นผู้นำแพทย์-นักวิทยาศาสตร์ที่มีประสบการณ์อย่างลึกซึ้ง ส่วน Jen เป็นผู้นำด้านการเงินด้านการดูแลสุขภาพและการพัฒนาองค์กรที่ช่ำชอง ด้วยประสบการณ์การเป็นผู้นำในอุตสาหกรรมมานานหลายทศวรรษ พวกเขาแต่ละคนจะเข้ามาเป็นกำลังเสริมอันทรงคุณค่าของ Zenas ในขณะที่เรามุ่งหน้าสู่ระยะต่อไปของการเติบโต โดยพัฒนาโครงการระดับโลกหลายโครงการในการพัฒนาทางคลินิกระยะสุดท้ายโดยมีเป้าหมายเพื่อส่งมอบการรักษา I&I ทางตรงที่แตกต่างให้แก่ผู้ป่วยที่ต้องการความช่วยเหลือทั่วโลก”

คุณ Fox เป็นผู้บริหารการเงินและการพัฒนาองค์กรที่มีประสบการณ์ โดยมีประวัติที่กว้างขวางในด้านการเงินองค์กรและวาณิชธนกิจด้านการดูแลสุขภาพ โดยให้คำปรึกษาแก่บริษัทเอกชนและบริษัทมหาชนหลายแห่งเกี่ยวกับกลยุทธ์ การจัดหาเงินทุน และการควบรวมและซื้อกิจการ ก่อนที่จะมาร่วมงานกับ Zenas คุณ Fox ดำรงตำแหน่งประธานเจ้าหน้าที่ฝ่ายการเงินที่ Nuvation Bio ซึ่งเป็นบริษัทเทคโนโลยีชีวภาพที่มีการซื้อขายในตลาดหลักทรัพย์ ก่อนหน้านี้เธอเคยดำรงตำแหน่งกรรมการผู้จัดการและหัวหน้าร่วมของ North America Healthcare Corporate and Investment Banking Group ที่ CitiGroup ก่อนที่จะมาร่วมงานกับ CitiGroup คุณ Fox ดำรงตำแหน่งอาวุโสในด้านวาณิชธนกิจที่ Deutsche Bank, Bear Stearns, Bank of America และ Prudential Securities เธอถือวิทยาศาสตรบัณฑิตสาขาการเงินและการตลาดจากมหาวิทยาลัย Manhattan

Dr. Fischer เป็นแพทย์-นักวิทยาศาสตร์ที่มีประสบการณ์เชิงลึกในด้านวิชาการและในบริษัทเภสัชกรรมและเทคโนโลยีชีวภาพ โดยเป็นผู้นำโครงการวิจัยและพัฒนาในระยะเริ่มแรกและระยะสุดท้ายในสาขาการรักษาที่หลากหลาย ซึ่งรวมถึงประสาทวิทยาและโรคหายาก ก่อนที่จะมาร่วมงานกับ Zenas เธอดำรงตำแหน่งประธานเจ้าหน้าที่ฝ่ายพัฒนาและหัวหน้าฝ่ายการแพทย์เฉพาะทางที่ Biohaven ซึ่งเป็นบริษัทชีวเภสัชภัณฑ์ที่มีการซื้อขายในตลาดหลักทรัพย์ Dr. Fischer เริ่มต้นอาชีพในอุตสาหกรรมของเธอที่ Bristol Myers Squibb และดำรงตำแหน่งผู้นำด้านการวิจัยและพัฒนาเพื่อการเพิ่มความรับผิดชอบที่ EMD-Serono, Sanofi-Genzyme และ Alnylam เธอเป็นนักประสาทวิทยาและได้รับการแต่งตั้งที่ Yale University School of Medicine หลังจากสำเร็จการศึกษาด้านประสาทวิทยาที่โรงพยาบาล Yale New Haven เธอสำเร็จการศึกษาระดับแพทยศาสตร์ (MD) และปริญญาปรัชญาดุษฎีบัณฑิต (PhD) จาก University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School และ Rutgers University ตามลำดับ และได้รับรางวัล Presidential Early Career Award for Scientists and Engineers (PECASE) อันทรงเกียรติ

ข้อมูลเกี่ยวกับ Zenas BioPharma

Zenas BioPharma เป็นบริษัทชีวเภสัชภัณฑ์ระดับโลกที่มุ่งมั่นที่จะเป็นผู้นำในการพัฒนาและทำธุรกิจด้านการรักษาการอักเสบและภูมิคุ้มกันวิทยา (I&I) ทางตรงให้แก่ผู้ป่วยที่ต้องการความช่วยเหลือทั่วโลก Zenas กำลังพัฒนาพอร์ตผลงานการรักษาภูมิต้านตนเองที่อาจสร้างความแตกต่างในด้านความจำเป็นทางการแพทย์ที่ไม่ได้รับการตอบรับในระดับสูง (High unmet medical need) ด้วยความสามารถในการพัฒนาทางคลินิกและการปฏิบัติการในระดับโลก ทีมผู้นำที่มีประสบการณ์และเครือข่ายพันธมิตรทางธุรกิจของเราขับเคลื่อนความเป็นเลิศในการดำเนินงาน เพื่อส่งมอบการรักษาที่ก่อให้เกิดการเปลี่ยนแปลงที่เป็นไปได้ เพื่อปรับปรุงชีวิตของผู้ที่เผชิญกับโรคภูมิต้านทานตนเองและโรคที่พบได้ยากต่าง ๆ ให้ดีขึ้น สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Zenas BioPharma โปรดไปที่ www.zenasbio.com และติดตามพวกเราใน Twitter ที่ @ZenasBioPharma และ LinkedIn

เกี่ยวกับ Obexelimab

Obexelimab เป็นโมโนโคลนอลแอนติบอดีที่ผลิตจากสัตว์ทดลอง ไม่ทำลายเซลล์ มีสองปลาย อยู่ในระยะที่ 3 ของการวิจัยซึ่งเลียนแบบการทำงานของสารประกอบเชิงซ้อนแอนติเจน-แอนติบอดี โดยสร้างพันธะกับCD19 และ FcγRIIb เพื่อยับยั้งการทำงานของสายพันธุ์บีเซลล์ อาสาสมัคร 198 คนได้รับการรักษาด้วย Obexelimab ในระหว่างการวิจัยทางคลินิกระยะเริ่มแรกหลายครั้ง ซึ่งรวมถึงโรคภูมิต้านตนเองหลายชนิด ในการวิจัยทางคลินิกเหล่านี้ Obexelimab ได้แสดงให้เห็นถึงการยับยั้งการทำงานของบีเซลล์ได้อย่างมีประสิทธิภาพโดยไม่ทำลายเซลล์ และให้ผลการรักษาที่สร้างกำลังใจให้แก่ผู้ป่วยโรคภูมิต้านตนเองหลายชนิด Zenas ได้รับสิทธิทั่วโลกแต่เพียงผู้เดียวในการใช้ Obexelimab จาก Xencor, Inc. ขณะนี้ Obexelimab กำลังอยู่ในระหว่างการศึกษาทางคลินิกระยะที่ 3 ทั่วโลกในผู้ป่วยโรคที่เกี่ยวข้องกับอิมมูโนโกลบูลินจี 4 (IgG4 Related Disease) และการศึกษาระยะที่ 2/3 ในระดับโลกในผู้ป่วยภาวะโลหิตจางที่เกิดจากการแตกทำลายของเม็ดเลือดแดง (wAIHA) ชนิดที่แอนติบอดีทำงานได้ดีในอุณหภูมิอบอุ่น (Warm) การพัฒนาทางคลินิกของ Obexelimab สำหรับโรคปลอกประสาทเสื่อมแข็ง (Multiple Sclerosis) และโรคแพ้ภูมิตัวเอง (Systemic Lupus Erythematosus) กำลังอยู่ในระหว่างการประเมิน

ดูข้อมูลเพิ่มเติมเกี่ยวกับการวิจัยระยะที่ 3 (INDIGO) สำหรับการรักษาโรคที่เกี่ยวข้องกับ IgG4 ได้ที่ clinictrials.gov: NCT05662241 ดูข้อมูลเพิ่มเติมเกี่ยวกับการวิจัยระยะที่ 3 (SApHiAre) สำหรับการรักษาโรค wAIHA ได้ที่ clinictrials.gov: NCT05786573

ติดต่อด้านนักลงทุนและสื่อ:
Joe Farmer ประธานและกรรมการผู้อํานวยการฝ่ายปฏิบัติการ
Zenas BioPharma
IR@zenasbio.com

GlobeNewswire Distribution ID 8988518

A Media Snippet accompanying this announcement is available by clicking on this link.

• Most successful dinosaur exhibit of all-time
• More than 1.5 million visitors see Barbara and Peter – a world-first male & female T. rex pairing
• Barbara is one of only three female T. rex specimens ever discovered
• Auckland Museum breaks new ground by open access publication of scientific research of the specimens
• Visitor numbers equivalent to a third of the population of New Zealand have seen the Barbara and Peter T. rex exhibit

AUCKLAND, New Zealand and LONDON, Dec. 04, 2023 (GLOBE NEWSWIRE) — With just days left to run, the world’s first display of an adult male and female T.rex side by side is believed to be the most successful dinosaur exhibition of all time.

Already, 1.5 million people have visited Auckland Museum to see this spectacular exhibition, which has run for a year, and which will draw to a close on December 10, 2023. Given that New Zealand itself has a population of just 5.1 million inhabitants, the numbers who came to see the two T.rex dinosaurs, named Barbara and Peter, are unprecedented.

David Reeves, CEO of Auckland Museum, hailed the impact of the exhibition: “Not only have we seen visitor numbers equivalent to almost the whole of Auckland’s population of 1.6 million come through the doors, but Barbara and Peter have provided a once-in-a-lifetime, educational experience for many, many thousands of school children. It has been a joy to see people’s reactions as they encounter these magnificent specimens for the first time.”

Tyrannosaurus rex fossils are extremely rare, with only about 20 T. rex on display in museums worldwide. These were the first T. rex exhibits in the Southern Hemisphere. The world’s most famous dinosaur is so scarce that there is no T. rex on permanent exhibit in the Middle East, the whole of Asia, Africa or Latin America. There are only four T. rex on display in Europe.

Female T. rex specimens are rarer still, with Barbara representing only the third ever pregnant Tyrannosaurus rex dinosaur skeleton to be discovered. Barbara is 44.7 per cent complete, making her the 8th most complete T. rex in the world. She measures an impressive 11.7 metres long and 3.4m high.

Close viewing of the T.rex reveals some of the incredible anatomical features of one of the largest land predators of all time and offers the ability to inspect injuries that pathological findings revealed, specifically an injury to Barbara’s leg, likely to have been caused by another T.rex. It is remarkable that a massive animal like Barbara, which relied on walking or running on two legs as the primary method of locomotion, could survive such an injury. She lived for a long period after the injury, as can be seen by the evidence of a healed metatarsal.

Dr Andre Lujan, President of the Association of Applied Paleontological Sciences, said: “The Auckland Museum should be congratulated on this ground-breaking world first exhibit of a male and female T.rex together. Visitor numbers show that a huge percentage of New Zealand’s children got to see these magnificent specimens, which is a wonderful inspiration for the next generation of paleontologists.”

Alongside the exhibiting of Barbara and Peter, Auckland Museum has made public the preliminary scientific research on the specimens, undertaken by expert academics. According to David Reeves: “The publication of this research, made available to the museum and its visitors, is a novel and hugely important concept, designed to bridge the gap for the lay observer between the learned, peer-reviewed academic reports and the very limited data typically supplied to visitors by museums in support of such exhibits. This has truly ignited the imagination of young scientists in New Zealand.”

These preliminary reports have been prepared by two of the world’s top theropod paleontologists, Dr David Burnham (University of Kansas Biodiversity Institute and Natural History Museum) and Dr John Nudds (Department of Earth and Environmental Sciences, University of Manchester), who studied both Barbara and Peter in their university laboratories for many months.

Dr Nudds commented: “These reports are designed to encourage children and young people to learn about the extraordinary world of theropods, a subject that has fascinated me for my entire professional life.”

Dr Burnham added: “Barbara and Peter each represents an individual animal that was a living and breathing organism. Studying and reporting publicly about each individual specimen means it becomes part of the entire body of knowledge about Tyrannosaurus rex. Therefore, every documented specimen counts enormously, not least because there are so very few.”

This unique display, together with published research, has afforded the public to gain a deeper understanding of the history and mysteries of the T.rex, providing insights into their origins, lives, and the remarkable process of finding and mounting fossil specimens.

The exhibition will close soon, but already 1.5 million people have been thrilled by the once-in-a-lifetime opportunity to stand face-to-face with two real T. rex, brought together for the first time in 66 million years.

For further information

Seven Dials City

Simon Kelner
simon@sevendialspr.com
+44 7775 788898

James Devas
james@sevendialscity.com
+44 7885 813 114

ABOUT AUCKLAND WAR MEMORIAL MUSEUM

Auckland War Memorial Museum is one of New Zealand’s first museums. The Museum tells the story of New Zealand, its place in the Pacific and its people. The Museum is a war memorial for the province of Auckland and holds one of New Zealand’s top three heritage libraries. It has pre-eminent Māori and Pacific collections, significant natural history resources and major social and military history collections, as well as decorative arts and pictorial collections.

GlobeNewswire Distribution ID 1000902476

The fund is focused on investment in greenfield renewable energy infrastructure in high growth middle-income markets and is expected to enable more than 10 GW of clean energy

COPENHAGEN, Denmark , Dec. 04, 2023 (GLOBE NEWSWIRE) — Today, Copenhagen Infrastructure Partners (CIP) announced the launch of its Growth Markets Fund II (GMF II), during the 2023 United Nations Climate Change Conference (COP 28) in Dubai. With a focus on developing and building offshore and onshore wind, solar PV, energy storage and Power-to-X projects in selected high growth middle-income markets across Asia, Latin America and EMEA, the fund has a target size of USD 3 billion and is expected to deliver renewable energy infrastructure projects reflecting over USD 10 billion of capital investment. This will enable more than 10 GW of new renewable energy capacity. It is set to be the world’s largest fund focused on greenfield renewable energy investments in high growth, middle-income markets.

“To reach net-zero, we need to bring affordable, reliable, and clean energy to all parts of the world. With a continuous increase in carbon emissions, successful deployment of large-scale renewable energy is particularly important in high-growth, middle-income countries. This fund will be deploying significant private capital and therefore ensure renewable projects in countries, where it will contribute to growth and job creation and deliver substantial impact in terms of reducing carbon emissions,” said Christina Grumstrup Sørensen, Senior Partner and founder of CIP.

By all estimates, emissions from middle-income markets are expected to grow dramatically over the coming decades. Renewable energy power capacity will need to at least triple by 2030 for the global community to stay on the path to net-zero. To achieve these capacity goals, investments into clean energy must more than quadruple, and middle-income and emerging markets alone will need investments of more than USD 1.9 trillion by 2030. The GMF II fund will play an important part in reaching and realizing these goals.

“These middle-income and emerging markets represent not only a mandatory task for the industry – and we believe that they are also very attractive markets for investors seeking exposure to the some of the highest expected growth rates for renewables. They are estimated to account for 25% of global renewable energy capacity by 2050, as economic and demographic growth drives rapidly increasing electricity demand,” said Niels Holst, partner at CIP and co-head of GMF.

“With GMF II we are applying our proven greenfield and industrial investment approach from our predecessor funds to create excess returns while significantly mitigating risks. The fund is off to a good start with a large and diversified portfolio of projects reflecting potential equity commitments of more than USD 5 billion – far exceeding the target fund size. We expect the fund to be a global driver in the green and just transition,” said Ole Kjems Sørensen, Partner at CIP and co-head of GMF.

Based on GMF II’s already existing portfolio of renewable energy development projects, the fund has the potential to reduce greenhouse gas emissions by more than 10 millon tonnes annually, while powering more than 10 million homes with clean energy and creating more than 100,000 full-time equivalent (FTE) years globally.

The launch of GMF II adds to what has already been a record year at CIP in 2023, with first close of the fifth flagship fund, Copenhagen Infrastructure V (CI V), at nearly EUR 6 billion as well as final close of both the Advanced Bioenergy Fund I and Green Credit Fund I at a combined EUR ~2 billion. GMF II is CIP’s 12th fund.

About Growth Markets Fund II
GMF II will focus on investments in large-scale and complex greenfield renewable energy infrastructure projects in high-growth middle-income markets with strong fundamentals for renewable development and significant impact potential.

The fund is targeting 15 selected high-growth middle-income markets across Asia, Latin America and EMEA, such as India, Vietnam, Philippines, Mexico, and South Africa. These markets have strong fundamentals for renewable energy infrastructure investments with a combination of high economic and demographic growth including an expanding middle class leading to an accelerating electricity demand.

GMF II markets are expected to account for 25% of global installed renewables capacity by 2050. These markets present significant potential for offshore wind which is estimated to expand about 50 times from 2022 to 2035 and become an important driver for green transition in GMF II markets.

The fund has ownership to a diversified portfolio of attractive development stage projects across offshore wind, onshore wind, solar PV, battery storage and Power-to-X representing more than USD 5 billion in potential commitments – significantly exceed the target fund size of USD 3 billion. These proprietary projects represent actual investment opportunities and provide the fund with relatively high execution certainty, pace of capital deployment and visibility (not a blind pool), as CIP has already worked on these projects for several years.

GMF II is a successor fund to Growth Markets Fund I launched in 2019. In addition to the large project portfolio, the fund will benefit from a global, established, and dedicated Growth Market team of over 70 people with an already extensive local presence in key markets, combined with CIP’s experience and track-record in greenfield industrial value creation.

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages 12 funds and has to date raised approximately EUR 26 billion for investments in energy and associated infrastructure from more than 150 international institutional investors. CIP has approximately 400 employees and 12 offices around the world. For more information, visit www.cip.com

For further information, please contact:
E-mail: media@cip.com

Oliver Routhe Skov, Head of Media Relations
Phone: +45 30541227
Email: orsk@cip.com

Stephanie Brokhattingen, Partner – Investor Relations
Phone: +45 7070 5151
Email: sbr@cip.com

Thomas Kønig, Partner – Investor Relations
Phone: +45 7070 5151
Email: tkon@cip.com

Legal disclaimer
This release does not constitute an offer to sell or the solicitation of an offer to purchase any security. Any investment involves substantial risks including complete loss of capital. There can be no assurance that CIP will be able to implement the strategy described herein or, if implemented, that it will lead to successful results. Similarly, there can be no assurance that CIP will be able to maintain the advantages discussed herein over time, or outperform third parties or the financial markets generally.

Certain information contained herein constitutes “forward-looking statements,” which can be identified by the use of terms such as “may,” “will,” “expects,” “intends,” “plans,” “believes,” “estimates” or comparable terminology. Forward-looking statements are subject to a number of known and unknown risks and uncertainties, including without limitation changes in economic conditions, political changes, legal and regulatory requirements, interest rate fluctuations, as well as changes in markets, prospects and competition. There can be no assurance that historical trends will continue. Some of the views expressed herein are the opinions of CIP and should not be construed as absolute statements and are subject to change without notice.

GlobeNewswire Distribution ID 1000902389

BANGALORE, India, Dec. 04, 2023 (GLOBE NEWSWIRE) — OKX, a leading Web3 technology company, today announced its sponsorship of key events at India Blockchain Week (IBW), which takes place from December 4-10 at Sheraton Grand Whitefield, Bangalore. During the week, OKX will sponsor Polygon Connect on December 7 and ETH India from Dec 8-10, and will co-host two developer mixers.

IBW is India’s flagship series of blockchain and Web3 events, which aims to bring together the brightest minds in the blockchain space to explore and discuss the latest developments and innovations in Web3.

Polygon Connect will take place on December 7, from 9:00 (IST) to 18:00 (IST) at Bengaluru Marriot Hotel, Whitefield. Polygon Connect is part of a global initiative that unites every part of Polygon’s ecosystem via live events, hackathons and community gatherings.

During Polygon Connect, OKX Director of Product (Web3) Ankit Bhatia will present a keynote speech from 11:45 (IST) to 12:00 (IST) on the main stage. The keynote will focus on OKX’s Web3 solutions, including X1, the exchange’s new, highly performant and secure Ethereum-based Zero Knowledge (ZK) Layer-2 (L2) network, built with the Polygon Chain Development Kit (CDK). He will also participate in a panel discussion titled ‘Abstracting the Essence of Web3’ from 17:00 (IST) to 17:30 (IST).

ETH India is a hackathon that takes place from December 8-10, from 9:00 (IST) to 18:00 (IST) each day at KTPO Convention Centre, Whitefield. OKX will host its own hackathon at the event to support the development of its X1 zkEVM Layer 2 network, with a prize of USD5,000 awarded to the best X1-related project idea. Attendees who visit OKX’s booth and mint an NFT for free via the OKX NFT Marketplace will also have the opportunity to receive limited-edition OKX-branded swag items, such as cricket balls.

As part of its participation in IBW, OKX will also co-host two side events:

• Builder’s Mixer – Bengaluru: This event will take place on December 5 from 19:00 (IST) to 22:00 (IST) at Biergarten Whitefield. OKX is co-hosting the mixer with EthSign, TokenTable and Particle Network with the aim of bringing together talents who are building and supporting Web3 infrastructure initiatives under one roof. Event attendees will be gifted an ‘OKX Project X NFT Entry Ticket.’ Built on the OKT Chain and hosted on OKX Wallet, the ‘OKX Project X NFT Entry Ticket‘ serves as both a digital collectible and ticket to the Builder’s Mixer.
• Project X: This networking party will take place on December 8 from 19:30 (IST) to 23:00 (IST) at the Big Bang Sky Deck & Lounge. OKX is co-hosting this event with CapX, Polygon and Manta Pacific to celebrate innovation, collaboration and the future of Polygon’s CDK. Attendees will also receive an NFT to gain entry into Project X.

During IBW, users based in India who follow OKX India’s X (formerly known as Twitter), download OKX Wallet and top up their wallet with crypto will be eligible to enter a giveaway with the opportunity to claim a share in a prize pool worth 2,000 MATIC tokens*. In addition, OKX Head of Product Marketing (Web3) Thomas Chou will attend an IBW panel discussion titled ‘Maximizing Global Reach: GTM Strategies for Web3’ on December 7. During the discussion, he will share his strategies for Web3 product innovation alongside panelists from Kyber Network, Caliber, Mantle and Polygon on the second stage at Sheraton Grand Whitefield.

OKX Chief Marketing Officer Haider Rafique said: “We prioritize strengthening relationships with Web3 developers and builders in India and globally. By sponsoring and co-hosting India Blockchain Week events, we will engage with developers, thinkers and entrepreneurs who we hope will be interested in shaping the growth of our Web3 innovations, including the newly launched X1 network. We’re excited to make a strong impact in the thriving Indian developer community this week.”

This announcement follows the recent launch of OKX’s cricket-themed ‘Be a Crypto Player‘ ad campaign. Strategically timed to coincide with the 2023 international cricket championship final between India and Australia in Ahmedabad on November 19, the campaign positions OKX as a key Web3 player in India and showcases its comprehensive suite of Web3 products. The ad, available in Hindi in addition to English, marks OKX’s recent addition of Hindi support to its Web3 wallet.

To learn more about India Blockchain Week, click here.

*Further details on the MATIC giveaway can be found here.

For further information, please contact:
Media@okx.com

Disclaimer

GlobeNewswire Distribution ID 8988740